SILVIA ROSADO GARCIA

SILVIA ROSADO GARCIA

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2009 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
SMSusana Mellor‐Pita
Susana Mellor‐Pita
MCMaria J. Citores
Maria J. Citores
RCRaquel Castejon
Raquel Castejon
MYMiguel Yebra‐Bango
Miguel Yebra‐Bango
PTPablo Tutor‐Ureta
Pablo Tutor‐Ureta
JVJuan A. Vargas
Juan A. Vargas

22 November 2013 in Rheumatology
Verified
Journal Article
Open access
PDF file
RCRaquel Castejon
Raquel Castejon
CJCarlos Jimenez-Ortiz
Carlos Jimenez-Ortiz
SVSara Valero-Gonzalez
Sara Valero-Gonzalez
SGSILVIA ROSADO GARCIA
SILVIA ROSADO GARCIA
SMSusana Mellor
Susana Mellor
MYMiguel Yebra-Bango
Miguel Yebra-Bango
Objective. Endothelial progenitor cells (EPCs) play an important role in vascular damage repair and it has been suggested that a decreased number of these cells is associated with increased subclinical atherosclerosis. Our study aim was to evaluate whether the number of circulating EPCs in patients with SLE is associated with subclinical atherosclerosis, the presence of cardiovascular (CV) risk factors and SLE-specific factors. Methods. Forty-six female SLE patients were included. At the time of each patient’s appointment, CV risk factors, SLE-specific factors and EPCs were assessed in peripheral blood by flow cytometry. Simultaneously, atherosclerosis was assessed by measuring the carotid–femoral pulse wave velocity (PWV) by Doppler velocimetry, intima media thickness (IMT) and carotid plaque by B-mode US scanning. Results. Patients were classificated according to PWV following the reference values adjusted by age and blood pressure published by the European Society of Cardiology. Patients with pathological values of PWV showed a significant decrease of circulating EPC percentage compared with normal PWV patients. Decreased EPC counts were also associated with certain risk factors, including hypertension, tobacco use, impaired glucose metabolism, and metabolic syndrome, and correlate with high levels of high-sensitivity CRP (hsCRP) or fibrinogen. The presence of carotid plaque and IMT measurement were unrelated with EPC quantification. Conclusion. Patients with a reduced percentage of EPCs showed pathological arterial stiffness and association with certain CV risk factors, suggesting that the measurement of circulating EPCs can be used as a biological marker to determine subclinical atherosclerosis in SLE.

1 January 2008 in Human Immunology
Verified
Journal Article
Closed access
SGSILVIA ROSADO GARCIA
SILVIA ROSADO GARCIA
GPGema Perez-Chacon
Gema Perez-Chacon
SMSusana Mellor-Pita
Susana Mellor-Pita
ISInmaculada Sanchez-Vegazo
Inmaculada Sanchez-Vegazo
CBCarmen Bellas-Menendez
Carmen Bellas-Menendez
PPPaloma Perez-Aciego
Paloma Perez-Aciego

25 November 2020 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
MMMaría Martinez-Urbistondo
María Martinez-Urbistondo
AMAlberto Mora-Vargas
Alberto Mora-Vargas
EEEsther Expósito-Palomo
Esther Expósito-Palomo
RCRaquel Castejón
Raquel Castejón
MCM. Jesús Citores
M. Jesús Citores
JMJ. Alfredo Martinez
J. Alfredo Martinez
Background. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) infection elicits inflammatory manifestations that relate with a cytokine storm. Objective. The aim of this research was to assess the role of circulating interleukin 6 (IL-6) levels and other inflammatory markers in patients with coronavirus disease 2019 (COVID-19) on metabolic functions and accompanying clinical complications. Patients and Methods. A total of 165 patients diagnosed with COVID-19 pneumonia were examined for medical features and inflammatory markers such as blood IL-6, CRP, ferritin, LDH, neutrophil/lymphocyte index (NLI), D-Dimer, and Red Cell Distribution Width (RDW). Regression analyses concerning electronically collected medical data were adjusted by appropriate factors and confounding variables. Results. Plasma IL-6 determinations evidenced a consistent association with hospital stay days, Intensive Care Unit (ICU) admission, and mortality rates. Similar trends were found for other proinflammatory variables, where ferritin and NLI showed a remarkable value as surrogates. Hyperglycaemia and the Charlson Comorbidity Index Score were positively associated with the inflammatory response induced by the SARS-COV-2 infection. An unhealthy lifestyle such as smoking and alcoholic drinks consumption as well as excessive body adiposity influenced inflammatory-related outcomes in the screened patients. Conclusion. IL-6 together with other inflammatory biomarkers accompanied poor clinical and metabolic outcomes in COVID-19-infected patients. IL-6 may result in a suitable proxy to individually categorise patients in order to manage this infectious pandemic.

8 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VMVictor Moreno-Torres
Victor Moreno-Torres
CTCarlos Tarín
Carlos Tarín
GRGuillermo Ruiz-Irastorza
Guillermo Ruiz-Irastorza
RCRaquel Castejón
Raquel Castejón
ÁGÁngela Gutiérrez-Rojas
Ángela Gutiérrez-Rojas
AVAna Vicente
Ana Vicente
Background: the admission and death causes of SLE patients might have changed over the last years. Methods: Analysis of the Spanish National Hospital Discharge database. All individuals admitted with SLE, according to ICD-9, were selected. The following five admission categories were considered: SLE, cardiovascular disease (CVD), neoplasm, infection, and venous-thromboembolic disease (VTED), along four periods of time (1997–2000, 2001–2005, 2006–2010, and 2011–2015). Results: The admissions (99,859) from 43.432 patients with SLE were included. The absolute number of admissions increased from 15,807 in 1997–2000 to 31,977 in 2011–2015. SLE decreased as a cause of admission (from 47.1% to 20.8%, p < 0.001), while other categories increased over the time, as follows: 5% to 8.6% for CVD, 8.2% to 13% for infection, and 1.4% to 5.5% for neoplasm (p < 0.001 for all). The admission mortality rate rose from 2.22% to 3.06% (p < 0.001) and the causes of death evolved in parallel with the admission categories. A significant trend to older age was observed over time in the overall population and deceased patients (p < 0.001). Conclusions: Better control of SLE over the past two decades has led to a decrease in early admissions, and disease chronification. As a counterpart, CVD, infections, and neoplasm have become the main causes of admissions and mortality.

13 May 2022 in Journal of Translational Autoimmunity
Verified
Journal Article
Open access
VMVictor Moreno-Torres
Victor Moreno-Torres
RCRaquel Castejón
Raquel Castejón
SMSusana Mellor-Pita
Susana Mellor-Pita
PTPablo Tutor-Ureta
Pablo Tutor-Ureta
PCPedro Durán-Del Campo
Pedro Durán-Del Campo
JVJuan A. Vargas-Nuñez
Juan A. Vargas-Nuñez
Systemic Lupus Erythematosus (SLE) follow-up is based on clinical, and analytical parameters. We aimed to determine the differences between the Neutrophil-to-lymphocyte ratio (NLR), Platelet-to-lymphocyte ratio (PLR) and Red blood cell distribution width (RDW) between SLE patients and healthy controls and to assess their association with anemia status, classical inflammatory biomarkers and cytokines, disease activity, SLE related factors and treatment received for SLE. Seventy-seven patients with SLE according to 2012 SLICC criteria and 80 healthy controls were included. Patients with SLE were classified in SLE with anemia (SLE-a) and SLE without anemia (SLE-na). Statistical analysis between SLE patients and controls and the association of serological and clinical activity markers with proposed hematological indices among SLE patients were performed. RDW, NLR and PLR, were significantly higher in SLE patients than in healthy control group (p < 0.001), in SLE-a patients as compared to SLE-na (p < 0.0001) and were significantly associated with hypocomplementemia (p < 0.05). PLR was higher in active patients measured by SLEDAI-2K score and with longer disease duration (p < 0.05). RDW was associated with serological activity of the patients (p < 0.05) and was correlated with SLEDAI-2K and SLICC/ACR scores, hsCRP, D-dimer, fibrinogen, IL-6 and TNF as well as with corticosteroids intake (p = 0.05). A logistic regression analysis confirmed that after adjustment by age and hemoglobin values, RDW presented linear correlation with IL-6 levels (Beta-coefficient = 0.369, p = 0.003). NLR, PLR and RDW values suggest SLE serological and clinical activity. Given their availability, these markers not only could be useful tools to identify and monitor active SLE patients but whose application should be considered in inflammatory pathologies orchestrated by IL-6 and TNF.